特殊人群非小细胞肺癌的免疫治疗  

Immunotherapy for non-small cell lung cancer in special population

作　　者：赵志娟 熊洁[2] 何国华 赵萌 刘禹 赵育周 任小平[2] ZHAO Zhijuan;XIONG Jie;HE Guohua;ZHAO Meng;LIU Yu;ZHAO Yuzhou;REN Xiaoping(Xi'an Medical University,Xi'an,Shaanxi 710021,China;不详)

机构地区：[1]西安医学院,陕西西安710021 [2]陕西省人民医院呼吸危重症二科,陕西西安710068 [3]大兴医院呼吸危重症科,陕西西安710016

出　　处：《中国临床研究》2023年第6期816-820,共5页Chinese Journal of Clinical Research

基　　金：国家自然科学基金(2022JM-439)。

摘　　要：肺癌是全世界死亡比例最高的恶性疾病,根据病理学可划分为小细胞肺癌和非小细胞肺癌(NSCLC),其中NSCLC是最常见的。大多数患者在发现时已经是肺癌晚期,无法手术治疗,而传统的治疗存在各种的不足。免疫治疗不良反应小、作用持久,是继化疗、靶向治疗之外的又一项高效治疗手段,已经逐步跻身晚期NSCLC的一线治疗方案。在回顾NSCLC治疗中发现,现有的综述性研究均关注于常规人群,对于特殊人群关注十分有限。因此本文主要综述这类人群的免疫治疗。Lung cancer is a malignant disease with the highest mortality rate in the world,and it can be divided into small cell lung cancer and non-small cell lung cancer according to pathology.Non-small cell lung cancer is the most common.Most patients with lung cancer are diagnosed in an already advanced tumor stage when surgery is not an option for patients.However,traditional treatment has various shortcomings.With minimal adverse reactions and long-lasting effects,immunotherapy is another efficient treatment method in addition to chemotherapy and targeted therapy,and it has gradually become the first-line treatment for advanced non-small cell lung cancer.In view of the previous systematic reviews mainly on the general population,with limited attention to the special population,this article mainly summarizes the immunotherapy and focus in specific populations.

关 键 词：非小细胞肺癌 免疫治疗 老年人 慢性病毒感染 自身免疫性疾病 

分 类 号：R734.2[医药卫生—肿瘤]